oasis 1 trial oral semaglutide 50 mg obesity nejm 2023 Oral Semaglutide 25 mg and Orforglipron for Obesity: New NEJM Insights

Drug Watch: Orforglipron, a new oral option for treating obesity. Dr. Allan Brett summarizes what clinicians should know about this GLP-1 agonist. https://nej.md/48ReICG "For some patients, orforglipron might have an advantage because,

25.52

★★★★☆4.8 (126)

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

29.57

★★★★★4.9 (98)

Clinical Pharmacy Tuesday is here with a new journal club thanks to @highpoweredmedicine! The OASIS-4 trial evaluated oral semaglutide 25 mg for weight loss in adults with overweight or obesity without diabetes

25.42

★★★★★5.0 (157)

Semaglutide in Adults with Type 1 Diabetes and Obesity

25.18

★★★★★4.7 (84)

Now that oral semaglutide (#wegovy) is available, people want to know more about how the oral and injectable forms compare. First slide is the trial design. Second slide is average #weightloss of

21.29

★★★★★4.9 (203)

FDA has approved a new oral form of semaglutide for long-term weight reduction in adults with obesity or overweight. The new oral tablet is also indicated for reducing the risk of major

26.26

★★★★★5.0 (176)

Frontiers

23.08

★★★★★4.8 (132)